Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111803 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL3384423 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL1421214 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL7226415 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL4509965 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL589267 | 0.93 | SLC6A3 (0.54) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL17842115 | 0.88 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL1131039 | 0.86 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL6776456 | 0.84 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B | |
| SCHEMBL6775380 | 0.84 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6657065-B2 | Which are useful as microsomal triglyceride transfer protein (MTP) inhibitors | PFIZER INC | 2003-12-02 | — | — | US | claimed |
| US-20020161233-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-10-31 | — | — | US | claimed |
| US-20020042516-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-04-11 | — | — | US | claimed |
| US-11034691-B2 | Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-15 | — | — | US | disclosed |
| US-20190300527-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-03 | — | — | US | disclosed |
| US-10323029-B2 | Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-18 | — | — | US | disclosed |
| US-20170217963-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-20170217963-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2017-08-03 | — | — | US | disclosed |
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-6657065-B2 | Which are useful as microsomal triglyceride transfer protein (MTP) inhibitors | PFIZER INC | 2003-12-02 | — | — | US | disclosed |
| US-20020161233-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-10-31 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6417367-B1 | THAT ARE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS USEFUL FOR TREATING HYPERCHOLESTEROLEMIA FOR EXAMPLE; FEWER SYNTHESIS STEPS, STARTING MATERIALS ARE AN ACYL HALIDE AND M-NITROANILINE | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020042516-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-04-11 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099442-A2 | Methods of administering apo B-secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-1994022831-A1 | (S)-ALPHA-PHENYL-2-PYRIDINEETHANAMINE (S)-MALATE AND ITS USE AS A MEDICAMENT | ASTRA AKTIEBOLAG (SE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161233-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | SLC6A2 501/4885SLC6A4 954/4885SLC6A3 1239/4885 |
| US-20020042516-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | SLC6A2 501/4885SLC6A4 954/4885SLC6A3 1239/4885 |
| US-20170217963-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | S1PR1, SPHK1, S1PR3 | SLC6A2 2872/4885SLC6A4 3781/4885SLC6A3 3810/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | SLC6A2 2815/4885SLC6A4 3934/4885SLC6A3 3302/4885 |
| US-11034691-B2 | Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders | S1PR1, SPHK1, S1PR3 | SLC6A2 2872/4885SLC6A4 3781/4885SLC6A3 3810/4885 |
| US-20190300527-A1 | SPHINOGOSINE-1-PHOSPHATE RECEPTOR MODULATORS FOR TREATMENT OF CARDIOPULMONARY DISORDERS | S1PR1, SPHK1, S1PR3 | SLC6A2 2872/4885SLC6A4 3781/4885SLC6A3 3810/4885 |
| US-10323029-B2 | Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders | S1PR1, SPHK1, S1PR3 | SLC6A2 2872/4885SLC6A4 3781/4885SLC6A3 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.